Status:
TERMINATED
Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
Lead Sponsor:
University of Padova
Conditions:
Cirrhosis
Hepatorenal Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
From 1999, several studies have showed that the use of vasoconstrictors in association with albumin are effective in the treatment of hepatorenal syndrome (HRS). The rationale of the use of vasoconstr...
Eligibility Criteria
Inclusion
- Patients with cirrhosis and diagnosis of HRS type 1 or 2,serum creatinine \> 2.5 mg/dl
Exclusion
- Diagnosis of HCC with a staging beyond the Milan Criteria di Milano
- Septic shock (systolic arterial pressure \< 90 mmHg
- Significant heart or respiratory failure
- Peripheral arteriophaty clinically significant
- Previous heart stroke or significant alteration of the ECG
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00742339
Start Date
May 1 2005
End Date
October 1 2013
Last Update
October 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Clinical and Experimental Medicine, University of Padova
Padua, Italy, 35100